Trust Co. of Vermont Buys 313 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Trust Co. of Vermont increased its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 199.4% during the fourth quarter, HoldingsChannel reports. The firm owned 470 shares of the biopharmaceutical company’s stock after acquiring an additional 313 shares during the period. Trust Co. of Vermont’s holdings in Regeneron Pharmaceuticals were worth $335,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also bought and sold shares of the company. Rakuten Securities Inc. raised its stake in shares of Regeneron Pharmaceuticals by 380.0% in the third quarter. Rakuten Securities Inc. now owns 24 shares of the biopharmaceutical company’s stock valued at $25,000 after buying an additional 19 shares during the period. FSA Wealth Management LLC bought a new stake in Regeneron Pharmaceuticals in the 3rd quarter valued at about $26,000. Fairfield Financial Advisors LTD purchased a new stake in Regeneron Pharmaceuticals during the third quarter valued at about $37,000. Truvestments Capital LLC purchased a new stake in Regeneron Pharmaceuticals during the third quarter valued at about $39,000. Finally, Itau Unibanco Holding S.A. purchased a new position in shares of Regeneron Pharmaceuticals in the second quarter worth about $42,000. Hedge funds and other institutional investors own 83.31% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts recently commented on the stock. Canaccord Genuity Group cut shares of Regeneron Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, December 17th. UBS Group downgraded Regeneron Pharmaceuticals from a “buy” rating to a “neutral” rating and dropped their target price for the stock from $1,130.00 to $738.00 in a research report on Thursday. Barclays reduced their price target on Regeneron Pharmaceuticals from $1,080.00 to $1,065.00 and set an “overweight” rating for the company in a research report on Friday, November 1st. Piper Sandler dropped their price objective on Regeneron Pharmaceuticals from $1,242.00 to $1,195.00 and set an “overweight” rating on the stock in a report on Friday, November 1st. Finally, Evercore ISI reduced their target price on Regeneron Pharmaceuticals from $1,250.00 to $1,175.00 and set an “outperform” rating for the company in a report on Thursday, October 24th. One investment analyst has rated the stock with a sell rating, seven have assigned a hold rating, fifteen have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $1,015.38.

Regeneron Pharmaceuticals Trading Down 1.7 %

Shares of REGN opened at $681.58 on Monday. The firm has a market cap of $74.90 billion, a price-to-earnings ratio of 16.87, a PEG ratio of 1.60 and a beta of 0.10. The firm has a 50 day moving average price of $738.60 and a 200-day moving average price of $949.32. Regeneron Pharmaceuticals, Inc. has a fifty-two week low of $666.25 and a fifty-two week high of $1,211.20. The company has a debt-to-equity ratio of 0.09, a quick ratio of 4.46 and a current ratio of 5.28.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.